Zobrazeno 1 - 10
of 39
pro vyhledávání: '"Christoph Wanner"'
Autor:
Cheng Wang, Anuraag R. Kansal, Anastasia Ustyugova, Matthew Stargardter, Odette Reifsnider, Egon Pfarr, Christoph Wanner, Sarah Brand, Effie Kuti, Audrey Koitka-Weber
Publikováno v:
American Journal of Kidney Diseases. 79:796-806
Rationale & Objective Benefits of sodium-glucose co-transporter 2 inhibitors on kidney outcomes have been demonstrated in clinical trials. Among patients with type 2 diabetes and established cardiovascular (CV) disease enrolled in EMPA-REG Outcome St
Autor:
Anne Pernille Ofstad, Afshin Salsali, Erich Bluhmki, Martin Schumacher, Christoph Wanner, John M. Lachin, Silvio E. Inzucchi, Stefan Hantel, Kristin Ohneberg, Jyothis T. George, Claudia Schmoor, David Fitchett, Faiez Zannad, Bernard Zinman
Publikováno v:
ESC Heart Failure
ESC Heart Failure, Wiley, 2021, ⟨10.1002/ehf2.13615⟩
ESC Heart Failure, Vol 8, Iss 6, Pp 4517-4527 (2021)
ESC Heart Failure, 2021, ⟨10.1002/ehf2.13615⟩
ESC Heart Failure, Wiley, 2021, ⟨10.1002/ehf2.13615⟩
ESC Heart Failure, Vol 8, Iss 6, Pp 4517-4527 (2021)
ESC Heart Failure, 2021, ⟨10.1002/ehf2.13615⟩
International audience; Aims: In the EMPA-REG OUTCOME trial, empagliflozin reduced risk of death from heart failure (HF) or hospitalization for heart failure (HHF) versus placebo in patients with type 2 diabetes mellitus (T2DM) and established cardio
Autor:
Christoph Wanner, Stefan D. Anker, Waheed Jamal, Stuart J. Pocock, Gerasimos Filippatos, Milton Packer, Martina Brueckmann, Faiez Zannad, Javed Butler, João Pedro Ferreira, Cordula Zeller
Publikováno v:
New England Journal of Medicine. 385:1531-1533
Empagliflozin and Renal Outcomes in Heart Failure In a planned pooled analysis of two trials that evaluated empagliflozin in patients with heart failure, major adverse renal outcomes occurred in 2....
Autor:
Faiez, Zannad, João Pedro, Ferreira, John, Gregson, Bettina Johanna, Kraus, Michaela, Mattheus, Sibylle Jenny, Hauske, Javed, Butler, Gerasimos, Filippatos, Christoph, Wanner, Stefan D, Anker, Stuart J, Pocock, Milton, Packer
Publikováno v:
European Journal of Heart Failure
European Journal of Heart Failure, 2022, 24 (10), pp.1829-1839. ⟨10.1002/ejhf.2578⟩
European Journal of Heart Failure, 2022, 24 (10), pp.1829-1839. ⟨10.1002/ejhf.2578⟩
International audience; Aims: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) may induce an early post-initiation decrease of estimated glomerular filtration rate (eGFR), which does not impact the SGLT2i benefits. The occurrence, characteristics,
Autor:
Odd Erik Johansen, Christoph Wanner, Isabella Zwiener, Subodh Verma, Javed Butler, Jyothis T. George, Bernard Zinman, Silvio E. Inzucchi, C. David Mazer, Anne Pernille Ofstad
Publikováno v:
Diabetes, Obesity & Metabolism
Aim To determine the relationship between polyvascular disease and risk of hospitalization for heart failure (HHF) and cardiovascular (CV) death in the EMPA‐REG OUTCOME population, and the relationship of kidney dysfunction co‐existent with polyv
Autor:
Stefan Kaspers, Stuart J. Pocock, Stefan D. Anker, Michaela Mattheus, Silvio E. Inzucchi, Søren S Lund, Maximilian von Eynatten, Christoph Wanner, Jyothis T. George, Waheed Jamal, Stefan Hantel, Bernard Zinman, Odd Erik Johansen, David Fitchett, Ulrich Elsasser, Darren K. McGuire
Publikováno v:
The Lancet Diabetes & Endocrinology. 8:949-959
Patients with type 2 diabetes and atherosclerotic cardiovascular disease are at high clinical risk. We assessed the effect of the sodium-glucose co-transporter-2 inhibitor, empagliflozin, on total cardiovascular events and admissions to hospital in t
Autor:
Subodh Verma, Christoph Wanner, Isabella Zwiener, João Pedro Ferreira, Anne Pernille Ofstad, David Fitchett, Jyothis T. George, Bernard Zinman, Sabine Lauer, Silvio E. Inzucchi
Publikováno v:
Cardiovascular Diabetology, Vol 19, Iss 1, Pp 1-9 (2020)
Cardiovascular Diabetology
Cardiovascular Diabetology, BioMed Central, 2020, 19 (1), pp.200. ⟨10.1186/s12933-020-01174-6⟩
Cardiovascular Diabetology
Cardiovascular Diabetology, BioMed Central, 2020, 19 (1), pp.200. ⟨10.1186/s12933-020-01174-6⟩
BackgroundPatients with type 2 diabetes (T2D) and metabolic syndrome (MetS) are at greater cardiovascular risk than those with T2D without MetS. In the current report we aim to study the characteristics, cardio-renal outcomes and the effect of empagl
Autor:
Christoph Wanner, David C. Wheeler, Audrey Koitka-Weber, Stefan Hantel, Maximilian von Eynatten, Jyothis T. George, Adeera Levin, Vlado Perkovic
Publikováno v:
Clin J Am Soc Nephrol
Background and objectives In the Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG Outcome), empagliflozin, in addition to standard of care, significantly reduced risk of cardiovascular death by 38%, hosp
Autor:
Bernard Zinman, Michaela Mattheus, Silvio E. Inzucchi, Jyothis T. George, Kamlesh Khunti, Anne Pernille Ofstad, David Fitchett, Christoph Wanner
Publikováno v:
The Journal of Clinical Endocrinology and Metabolism
Context Control of multiple cardiovascular (CV) risk factors reduces CV events in individuals with type 2 diabetes. Objective To investigate this association in a contemporary clinical trial population, including how CV risk factor control affects th
Autor:
Nikolaus Marx, Christoph Wanner, Anne Pernille Ofstad, Jonathan Slawik, Michaela Mattheus, Subodh Verma, Silvio E. Inzucchi, David Fitchett, Jyothis T. George, Michael Böhm, Martina Brueckmann, Bernard Zinman, Stefan D. Anker
Publikováno v:
European Journal of Heart Failure. 22:126-135
Aims Atrial fibrillation (AF) is common in patients with diabetes and heart failure (HF) and increases the future risk of adverse cardiovascular (CV) outcomes. This analysis from the EMPA-REG OUTCOME trial explores CV and renal outcomes in patients w